ILLUMINATE-C, a Single-arm, Phase 3 Study of Lumasiran in Patients with Primary Hyperoxaluria Type 1 and CKD3b-5, Including Those on Hemodialysis

May 23, 2022

Collection: 2022 Posters

Type: Session

Speakers:

• Philip Arnold, MSN, RN

Tags: lumasiran oxalate Primary hyperoxaluria type 1 PH1lumasiran plasma oxalate cl impaired kidney function plasma clinical trial

ILLUMINATE-B, a Phase 3 open-label study to evaluate lumasiran, an RNAi therapeutic, in young children with primary hyperoxaluria type 1 (PH1)

Collection: 2021 Posters

Type: Session

Speakers:

• Hadas Sasha-Lavsky, MD
• Yaacov Frishberg, MD
• Kenji Fujita, MD
• Tracy McGregor, MD
• Akshay Vaishnaw, MD
• Pushkal Garg, MD
• Ali Seddighzadeh, MD
• Kyoungwha Bae, PhD
• Wesley Hayes, MD
• Debbie Barrera, BSN
• Gesa Schalk, MD
• David Sas, MD
• Mini Michael, MD
• William VantHoff, MD
• Daniella Magen, MD
• Pierre Cochat, MD
• Georges Deschenes, MD

Tags: primary hyperoxaluria type 1 PH1 lumasiran oxalate